Jorge Burns

Dr. Jorge Burns

University Politehnica of Bucharest
+1
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2004 in Oncogene
Verified
Journal Article
Closed access
PDF file
NSNedime Serakinci
Nedime Serakinci
PGPer Guldberg
Per Guldberg
JBJorge Burns
Jorge Burns
BABasem Abdallah
Basem Abdallah
HSHenrik Daa Schrøder
Henrik Daa Schrøder
MKMoustapha Kassem
Moustapha Kassem

10 June 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SFSteffen Fredersdorf
Steffen Fredersdorf
JBJorge Burns
Jorge Burns
AMAlistair M. Milne
Alistair M. Milne
GPGraham Packham
Graham Packham
LFLynn Fallis
Lynn Fallis
XLXin Lu
Xin Lu
The expression of cyclin-dependent kinase inhibitor p27 kip1 in human tumors and normal tissues was investigated using a panel of novel anti-p27 kip1 mAbs. An inverse correlation between expression of p27 kip1 and cell proliferation was generally observed after analyzing its expression in 25 different normal human tissues. In some highly proliferative human breast cancer cells, however, high level p27 kip1 expression was seen, indicating the existence of a mechanism by which some growing tumor cells may tolerate this inhibitor of cell cycle progression. Detailed studies demonstrated a correlation between the high level expression of p27 kip1 and cyclin D1 in human breast cancer cells. There was also an inverse correlation between the expression of p27 kip1 and the degree of tumor malignancy in human breast and colorectal cancers, indicating that p27 kip1 may be a useful prognostic marker in these cancers.

1 January 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
BABasem Abdallah
Basem Abdallah
MHMandana Haack-Sørensen
Mandana Haack-Sørensen
JBJorge Burns
Jorge Burns
BEBirgitte Elsnab
Birgitte Elsnab
FJFranz Jakob
Franz Jakob
MKMoustapha Kassem
Moustapha Kassem

1 January 2009 in Stem Cells and Development
Verified
Journal Article
Closed access
TPTatyana A. Prokhorova
Tatyana A. Prokhorova
LHLinda M. Harkness
Linda M. Harkness
UFUlrik Frandsen
Ulrik Frandsen
NDNicholas Ditzel
Nicholas Ditzel
HSHenrik Daa Schrøder
Henrik Daa Schrøder
MKMoustapha Kassem
Moustapha Kassem
When implanted into immunodeficient mice, human embryonic stem cells (hESCs) give rise to teratoma, tumor-like formations containing tissues belonging to all three germ layers. The ability to form teratoma is a sine qua non characteristic of pluripotent stem cells. However, limited data are available regarding the effects of implantation site and the methods employed for implantation on the success rate of teratoma formation. In this study, the rate of teratoma formation in immunodeficient mice was site dependent: subcutaneous (25–100%), intratesticular (60%), intramuscular (12.5%), and under the kidney capsule (100%). Co-injecting the hESCs with Matrigel increased subcutaneous teratoma formation efficiency from 25–40% to 80–100%. We did not observe site-specific differences in the teratoma composition at the histological level. However, subcutaneous teratomas were quite distinct, easy to remove, and caused minimal discomfort to the mice. Also, subcutaneous teratomas displayed larger proportion of solid tissues as opposed to cyst formation that dominated the teratomas formed at the other sites. Interestingly, a chromosomally abnormal hESCs with trisomy 20 formed teratomas where the ratio of differentiated to undifferentiated tissues was significantly decreased suggesting defective pluripotency of the cells. In conclusion, subcutaneous implantation of hESCs in presence of Matrigel appears to be the most efficient, reproducible, and the easiest approach for teratoma formation by hESCs. Also, teratoma formation can be employed to study the development defects exhibited by the chromosomally abnormal hESC lines.

Verified
Journal Article
Open access
PDF file
JBJorge Burns
Jorge Burns
Gina MandaGina Manda
Gina Manda
Focus on the Warburg effect, initially descriptive of increased glycolysis in cancer cells, has served to illuminate mitochondrial function in many other pathologies. This review explores our current understanding of the Warburg effect’s role in cancer, diabetes and ageing. We highlight how it can be regulated through a chain of oncogenic events, as a chosen response to impaired glucose metabolism or by chance acquisition of genetic changes associated with ageing. Such chain, choice or chance perspectives can be extended to help understand neurodegeneration, such as Alzheimer’s disease, providing clues with scope for therapeutic intervention. It is anticipated that exploration of Warburg effect pathways in extreme conditions, such as deep space, will provide further insights crucial for comprehending complex metabolic diseases, a frontier for medicine that remains equally significant for humanity in space and on earth.

1 July 2017 in Composites Part B: Engineering
Verified
Journal Article
Closed access
MIMariana Ioniţă
Mariana Ioniţă
GVGeorge Mihail Vlăsceanu
George Mihail Vlăsceanu
AWAiza Andreea Watzlawek
Aiza Andreea Watzlawek
SVStefan Ioan Voicu
Stefan Ioan Voicu
JBJorge Burns
Jorge Burns
Horia  IovuHoria Iovu
Horia Iovu